权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeting pancreatic cancer metastases with Targefrin

用 Targefrin 靶向胰腺癌转移

基本信息

批准号：
10763331
负责人：
Carlo Baggio
金额：
$ 40万
依托单位：
ARMIDA LABS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-14 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10763331
关键词：
Abraxane Adult Affinity Albumins Azoles Binding Biopsy Breast Cell Line Clinical Clinical Research Clinical Trials Cytotoxic agent Detection Development Dose Drug Targeting End Point Assay EphA2 Receptor Esters Evaluation FDA approved Formulation Future Invaded Investigational Therapies Letters Ligands Link Malignant Neoplasms Malignant neoplasm of pancreas Measurement Names Neoplasm Metastasis Normal tissue morphology Oncogenic Oncologist Organ Paclitaxel Pancreas Patient Selection Patients Penetration Pharmaceutical Preparations Phase Primary Neoplasm Prognosis Property Prostate Protocols documentation Receptor Cell Receptor Protein-Tyrosine Kinases Reporting Research Personnel Serum Side Signal Transduction Site Small Business Innovation Research Grant Solid Neoplasm Surface Surrogate Endpoint Testing Therapeutic Tissues Toxic effect Tumor Markers Xenograft Model anti-cancer cancer cell cell motility chemotherapeutic agent chemotherapy circulating cancer cell design diagnostic strategy efficacy study first-in-human gemcitabine imaging study in vivo in vivo Model in vivo imaging innovation neoplastic cell novel novel diagnostics novel therapeutic intervention overexpression pancreatic cancer cells pancreatic cancer model pancreatic neoplasm pharmacologic receptor receptor internalization standard of care targeted agent targeted treatment tumor

项目摘要

ABSTRACT We intend to devise a novel therapeutic strategy based on a specific cancer cell receptor named EphA2, which is abundant on the surface of metastatic pancreatic cancers. Over the past several years our studies focused on testing the anti-cancer potential of agents targeting the receptor in suppressing cell migration and invasion in cellular studies, as well as in inhibiting tumor metastases using in vivo models. Very recently we have derived the most effective agonistic agent reported to date that potently targets the EphA2 receptor and causes its degradation. In preliminary studies, the agent is remarkably effective in inhibiting pancreatic cancer cell migration. The agent also causes the internalization of the receptor; hence we intend to probe whether we can use this agent also to deliver chemotherapy selectively to pancreatic tumors.

摘要我们打算设计一种基于名为EphA 2的特异性癌细胞受体的新型治疗策略，在转移性胰腺癌的表面大量存在在过去的几年里，我们的研究集中在测试靶向受体的药物在抑制细胞迁移和侵袭方面的抗癌潜力细胞研究以及使用体内模型抑制肿瘤转移。最近我们得到了迄今为止报道的最有效的激动剂，其有效靶向EphA 2受体并引起其降解在初步研究中，该试剂对抑制胰腺癌细胞有显著效果，迁移该试剂也引起受体的内化;因此，我们打算探索我们是否可以也可以使用这种药物选择性地对胰腺肿瘤进行化疗。